About AUTL

AboutAutolus Therapeutics plcAutolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors.
Primary Exchange: NASDAQ
SIC Biological Products, (No Diagnostic Substances)
NAICS Biological Product (except Diagnostic) Manufacturing

AUTL is a Holding In These ETFs:

ETF Ticker ETF Name Net Assets Net Assets Raw # Holdings # Holdings Raw Weight Weight Raw Market Value Market Value Raw
BIB ProShares Ultra Nasdaq Biotechnology 219.3 M 2.1934E+08 234 234 0.02% 0.000178741 83 K 83173
UBIO Proshares UltraPro Nasdaq Biotechnology 29.3 M 2.93379E+07 227 227 0.01% 0.000114629 11 K 10621
IBB iShares Nasdaq Biotechnology Index Fund 7.4 B 7.39335E+09 221 221 0.04% 0.0004 3.2 M 3188020